Full-Time

Protein Engineer

Posted on 10/31/2025

UntilLabs

UntilLabs

51-200 employees

Advances reversible organ cryopreservation technology

Compensation Overview

$120k - $200k/yr

+ Equity

California, USA

In Person

Category
Biology & Biotech (4)
, , ,
Required Skills
Scikit-learn
Python
Tensorflow
Pytorch
Machine Learning
Pandas
NumPy
Requirements
  • 4+ years of industry experience or PhD/Postdoc training in Bioengineering, Computational Biology, Synthetic Biology, or a related field.
  • Experience in computational biology and machine learning-based approaches to predict new biomolecules, their activity, and expression in expression hosts.
  • High competence with Python and standard deep learning frameworks.
  • Expertise in engineering expression hosts (bacteria, yeast, and mammalian cells) to produce proteins, purify them, and assess stability and activity through functional assays.
  • Track record of scientific excellence and autonomy.
  • You bring a collaborative mindset and value diverse perspectives.
Responsibilities
  • Use innovative approaches to discover and characterize new biomaterials (anti-freeze proteins, peptides, biopolymers).
  • Train and evaluate machine learning models to predict new biomaterials to prevent ice formation, engineer expression hosts to produce them, and test their activity.
  • Closely collaborate with high throughput screening team to evaluate new biomaterials at preventing ice formation.
  • Effectively communicate analysis results to an interdisciplinary team.
Desired Qualifications
  • Expertise in strain and genome engineering, cloning, protein engineering, and protein expression.
  • Proficiency with advanced microscopy methods, including IHC, time-lapse imaging, TIRF, and super-resolution/light-sheet microscopy.

UntilLabs develops reversible cryopreservation technology to extend the viability of human organs for transplantation. The goal is to keep organs alive at cryogenic temperatures long enough to improve organ matching and reduce waste from time limits, potentially weeks or months of preserved time. The approach uses cooling to very low temperatures (below -130°C) with cryoprotectants to prevent ice damage, followed by advanced warming methods to revive the organs without harm. While cryopreservation has worked for cells and simple tissues, UntilLabs works on scaling this to whole organs, tackling challenges like ice formation and nutrient/waste management in large tissues. In the long term, the company envisions whole-body reversible cryopreservation as a bridge to future medical cures.

Company Size

51-200

Company Stage

N/A

Total Funding

N/A

Headquarters

San Francisco, California

Founded

2024

Simplify Jobs

Simplify's Take

What believers are saying

  • Raised $58M Series A in September 2025 from Founders Fund, Lux Capital, Field Ventures.
  • Enables organ banking, better matching, reduces waitlist deaths from time constraints.
  • Foundational for whole-body preservation, backed by over $100M funding.

What critics are saying

  • FDA lacks approval framework, delaying commercialization 3-5 years.
  • Normothermic systems from OrganOx, Transmedics capture market pre-approval.
  • Cryoprotectant toxicity triggers rejection, forces redesign in 24-36 months.

What makes UntilLabs unique

  • Until Labs develops reversible cryopreservation for organs using vitrification without ice formation.
  • Engineers five dimensions: perfusion, cryoprotectants, cooling, rewarming, and post-thaw assays.
  • Progressed from neural slices to preclinical kidneys, hearts, lungs, livers.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Flexible Work Hours

Paid Holidays

401(k) Retirement Plan

Health Savings Account/Flexible Spending Account

Commuter Benefits

Professional Development Budget

Company News

Pioneer Publishers
Sep 22nd, 2025
Until Labs Secures $58M for Cryopreservation

Until Labs announced a $58 million Series A funding round led by Founders Fund, with Lux Capital and Field Ventures participating. The company focuses on developing technology for organ-scale reversible cryopreservation, allowing donor organs to be preserved indefinitely and rewarmed for transplant. The funding will help expand their multidisciplinary team to enhance their cryopreservation methods, aiming to improve organ matching and reduce organ waste.

Fenwick
Sep 22nd, 2025
Fenwick Represents Until Labs in $58M Series A Funding

Fenwick represents Until Labs in $58M Series A funding.

INACTIVE